Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR3 is widely expressed in the early embryo but restricted to lymphatic vessels at later stages of development. VEGFR3 is up-regulated in tumor angiogenesis. VEGFC and VEGFD have been identified as ligands for VEGFR3. VEGFR3 plays a significant role in ligand-mediated lymphangiogenesis. Mutation in this gene is associated with the primary lymphedema, a rare genetic condition with both autosomal dominant and autosomal recessive modes of inheritance. The VEGFR3-mediated signaling pathway may provide a target for anti-lymphangiogenic therapy in cancer.

Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR3 is widely expressed in the early embryo but restricted to lymphatic vessels at later stages of development. VEGFR3 is up-regulated in tumor angiogenesis. VEGFC and VEGFD have been identified as ligands for VEGFR3. VEGFR3 plays a significant role in ligand-mediated lymphangiogenesis. Mutation in this gene is associated with the primary lymphedema, a rare genetic condition with both autosomal dominant and autosomal recessive modes of inheritance. The VEGFR3-mediated signaling pathway may provide a target for anti-lymphangiogenic therapy in cancer.

 

Product Details

 

Gene Symbol: FLT4; PCL; FLT-4; LMPH1A; VEGFR3

 

NCBI Gene ID: 2324

 

Uniprot Entry: P35916

 

Construct Details: Full length human FLT4 gene (encoding Uniprot#P35916-1) is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without a selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. Multiple choices of a stable antibiotic selection marker are available.

 

Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter +/- a selection marker, see the vector map above)

 

Formulation: Supplied with 10 μg of endotoxin-free plasmid DNA at 200 ng/μl in sterile TE buffer (pH8.0)

 

Gene Insert Size: 3897 (bp)

 

Gene Insert Sequence:  

ATGCAGCGGGGCGCCGCGCTGTGCCTGCGACTGTGGCTCTGCCTGGGACTCCTGGACGGCCTGGTGAGTG

GCTACTCCATGACCCCCCCGACCTTGAACATCACGGAGGAGTCACACGTCATCGACACCGGTGACAGCCT

GTCCATCTCCTGCAGGGGACAGCACCCCCTCGAGTGGGCTTGGCCAGGAGCTCAGGAGGCGCCAGCCACC

GGAGACAAGGACAGCGAGGACACGGGGGTGGTGCGAGACTGCGAGGGCACAGACGCCAGGCCCTACTGCA

AGGTGTTGCTGCTGCACGAGGTACATGCCAACGACACAGGCAGCTACGTCTGCTACTACAAGTACATCAA

GGCACGCATCGAGGGCACCACGGCCGCCAGCTCCTACGTGTTCGTGAGAGACTTTGAGCAGCCATTCATC

AACAAGCCTGACACGCTCTTGGTCAACAGGAAGGACGCCATGTGGGTGCCCTGTCTGGTGTCCATCCCCG

GCCTCAATGTCACGCTGCGCTCGCAAAGCTCGGTGCTGTGGCCAGACGGGCAGGAGGTGGTGTGGGATGA

CCGGCGGGGCATGCTCGTGTCCACGCCACTGCTGCACGATGCCCTGTACCTGCAGTGCGAGACCACCTGG

GGAGACCAGGACTTCCTTTCCAACCCCTTCCTGGTGCACATCACAGGCAACGAGCTCTATGACATCCAGC

TGTTGCCCAGGAAGTCGCTGGAGCTGCTGGTAGGGGAGAAGCTGGTCCTGAACTGCACCGTGTGGGCTGA

GTTTAACTCAGGTGTCACCTTTGACTGGGACTACCCAGGGAAGCAGGCAGAGCGGGGTAAGTGGGTGCCC

GAGCGACGCTCCCAGCAGACCCACACAGAACTCTCCAGCATCCTGACCATCCACAACGTCAGCCAGCACG

ACCTGGGCTCGTATGTGTGCAAGGCCAACAACGGCATCCAGCGATTTCGGGAGAGCACCGAGGTCATTGT

GCATGAAAATCCCTTCATCAGCGTCGAGTGGCTCAAAGGACCCATCCTGGAGGCCACGGCAGGAGACGAG

CTGGTGAAGCTGCCCGTGAAGCTGGCAGCGTACCCCCCGCCCGAGTTCCAGTGGTACAAGGATGGAAAGG

CACTGTCCGGGCGCCACAGTCCACATGCCCTGGTGCTCAAGGAGGTGACAGAGGCCAGCACAGGCACCTA

CACCCTCGCCCTGTGGAACTCCGCTGCTGGCCTGAGGCGCAACATCAGCCTGGAGCTGGTGGTGAATGTG

CCCCCCCAGATACATGAGAAGGAGGCCTCCTCCCCCAGCATCTACTCGCGTCACAGCCGCCAGGCCCTCA

CCTGCACGGCCTACGGGGTGCCCCTGCCTCTCAGCATCCAGTGGCACTGGCGGCCCTGGACACCCTGCAA

GATGTTTGCCCAGCGTAGTCTCCGGCGGCGGCAGCAGCAAGACCTCATGCCACAGTGCCGTGACTGGAGG

GCGGTGACCACGCAGGATGCCGTGAACCCCATCGAGAGCCTGGACACCTGGACCGAGTTTGTGGAGGGAA

AGAATAAGACTGTGAGCAAGCTGGTGATCCAGAATGCCAACGTGTCTGCCATGTACAAGTGTGTGGTCTC

CAACAAGGTGGGCCAGGATGAGCGGCTCATCTACTTCTATGTGACCACCATCCCCGACGGCTTCACCATC

GAATCCAAGCCATCCGAGGAGCTACTAGAGGGCCAGCCGGTGCTCCTGAGCTGCCAAGCCGACAGCTACA

AGTACGAGCATCTGCGCTGGTACCGCCTCAACCTGTCCACGCTGCACGATGCGCACGGGAACCCGCTTCT

GCTCGACTGCAAGAACGTGCATCTGTTCGCCACCCCTCTGGCCGCCAGCCTGGAGGAGGTGGCACCTGGG

GCGCGCCACGCCACGCTCAGCCTGAGTATCCCCCGCGTCGCGCCCGAGCACGAGGGCCACTATGTGTGCG

AAGTGCAAGACCGGCGCAGCCATGACAAGCACTGCCACAAGAAGTACCTGTCGGTGCAGGCCCTGGAAGC

CCCTCGGCTCACGCAGAACTTGACCGACCTCCTGGTGAACGTGAGCGACTCGCTGGAGATGCAGTGCTTG

GTGGCCGGAGCGCACGCGCCCAGCATCGTGTGGTACAAAGACGAGAGGCTGCTGGAGGAAAAGTCTGGAG

TCGACTTGGCGGACTCCAACCAGAAGCTGAGCATCCAGCGCGTGCGCGAGGAGGATGCGGGACGCTATCT

GTGCAGCGTGTGCAACGCCAAGGGCTGCGTCAACTCCTCCGCCAGCGTGGCCGTGGAAGGCTCCGAGGAT

AAGGGCAGCATGGAGATCGTGATCCTTGTCGGTACCGGCGTCATCGCTGTCTTCTTCTGGGTCCTCCTCC

TCCTCATCTTCTGTAACATGAGGAGGCCGGCCCACGCAGACATCAAGACGGGCTACCTGTCCATCATCAT

GGACCCCGGGGAGGTGCCTCTGGAGGAGCAATGCGAATACCTGTCCTACGATGCCAGCCAGTGGGAATTC

CCCCGAGAGCGGCTGCACCTGGGGAGAGTGCTCGGCTACGGCGCCTTCGGGAAGGTGGTGGAAGCCTCCG

CTTTCGGCATCCACAAGGGCAGCAGCTGTGACACCGTGGCCGTGAAAATGCTGAAAGAGGGCGCCACGGC

CAGCGAGCACCGCGCGCTGATGTCGGAGCTCAAGATCCTCATTCACATCGGCAACCACCTCAACGTGGTC

AACCTCCTCGGGGCGTGCACCAAGCCGCAGGGCCCCCTCATGGTGATCGTGGAGTTCTGCAAGTACGGCA

ACCTCTCCAACTTCCTGCGCGCCAAGCGGGACGCCTTCAGCCCCTGCGCGGAGAAGTCTCCCGAGCAGCG

CGGACGCTTCCGCGCCATGGTGGAGCTCGCCAGGCTGGATCGGAGGCGGCCGGGGAGCAGCGACAGGGTC

CTCTTCGCGCGGTTCTCGAAGACCGAGGGCGGAGCGAGGCGGGCTTCTCCAGACCAAGAAGCTGAGGACC

TGTGGCTGAGCCCGCTGACCATGGAAGATCTTGTCTGCTACAGCTTCCAGGTGGCCAGAGGGATGGAGTT

CCTGGCTTCCCGAAAGTGCATCCACAGAGACCTGGCTGCTCGGAACATTCTGCTGTCGGAAAGCGACGTG

GTGAAGATCTGTGACTTTGGCCTTGCCCGGGACATCTACAAAGACCCCGACTACGTCCGCAAGGGCAGTG

CCCGGCTGCCCCTGAAGTGGATGGCCCCTGAAAGCATCTTCGACAAGGTGTACACCACGCAGAGTGACGT

GTGGTCCTTTGGGGTGCTTCTCTGGGAGATCTTCTCTCTGGGGGCCTCCCCGTACCCTGGGGTGCAGATC

AATGAGGAGTTCTGCCAGCGGCTGAGAGACGGCACAAGGATGAGGGCCCCGGAGCTGGCCACTCCCGCCA

TACGCCGCATCATGCTGAACTGCTGGTCCGGAGACCCCAAGGCGAGACCTGCATTCTCGGAGCTGGTGGA

GATCCTGGGGGACCTGCTCCAGGGCAGGGGCCTGCAAGAGGAAGAGGAGGTCTGCATGGCCCCGCGCAGC

TCTCAGAGCTCAGAAGAGGGCAGCTTCTCGCAGGTGTCCACCATGGCCCTACACATCGCCCAGGCTGACG

CTGAGGACAGCCCGCCAAGCCTGCAGCGCCACAGCCTGGCCGCCAGGTATTACAACTGGGTGTCCTTTCC

CGGGTGCCTGGCCAGAGGGGCTGAGACCCGTGGTTCCTCCAGGATGAAGACATTTGAGGAATTCCCCATG

ACCCCAACGACCTACAAAGGCTCTGTGGACAACCAGACAGACAGTGGGATGGTGCTGGCCTCGGAGGAGT

TTGAGCAGATAGAGAGCAGGCATAGACAAGAAAGCGGCTTCAGGTAG

 

 

Primers: Gene insert coding sequence can be confirmed by following primers:

(a) forward (or 5'-end) primer: 5’-CAAATGGGCGGTAGGCGTG-3’;

(b) reverse (or 3'-end) primer: 5’-CCAGGTTTCCGGGCCCTCAC-3’

 

 

Note: The sequence may vary due to the naturally occurring variants or mutations, such as single nucleotide polymorphism, or the artifact during PCR amplification.  High fidelity PCR systems should always be used. 

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Cancer. Res. 52: 5738-5743 (1992).

2. Oncogene. 9: 3545-3555 (1994).

3. Proc. Natl. Acad. Sci. 95: 548-553 (1998).

4. FASEB. J. 15: 1028-1036 (2001).

5. Nature. 454: 656-660 (2008).

 

 

Additional supporting documents, including product data sheet (PDS), COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.